key: cord-1056305-1tr3f5qt authors: Dzobo, Mathias; Musuka, Godfrey; Mashe, Tapfumanei; Dzinamarira, Tafadzwa title: Inadequate SARS-CoV-2 Genetic Sequencing capacity in Zimbabwe: A call to urgently address this key gap to control current and future waves date: 2021-12-31 journal: IJID Regions DOI: 10.1016/j.ijregi.2021.09.004 sha: 615150d7207a8e35ecb74cf2e992afc4a91920cc doc_id: 1056305 cord_uid: 1tr3f5qt Zimbabwe continues to confront the COVID-19 pandemic; there is an urgent need for the rapid scale-up of genomic surveillance efforts. In this piece, we express concern on the limited capacity for SARS-CoV-2 genomic surveillance in Zimbabwe due to limited skillsets and laboratory infrastructural deficiencies. We call for an urgent need for funding from the government of Zimbabwe to set up a robust genomic surveillance program to detect SARS-CoV-2 variants of concern in Zimbabwe and guide public health responses accordingly. Zimbabwe continues to confront the COVID-19 pandemic; there is an urgent need for the rapid scale-up of genomic surveillance efforts. In this piece, we express concern on the limited capacity for SARS-CoV-2 genomic surveillance in Zimbabwe due to limited skillsets and laboratory infrastructural deficiencies. We call for an urgent need for funding from the government of Zimbabwe to set up a robust genomic surveillance program to detect SARS-CoV-2 variants of concern in Zimbabwe and guide public health responses accordingly. Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) that causes coronavirus disease-2019 (COVID-19) emerged in Wuhan, China in late 2019 ( Wang, C., Horby, P. W., Hayden, F. G., & Gao, G. F., 2020 ) . The virus has caused more than 191,000,000 million cases and 4,100,000 million deaths worldwide as of 18 July 2021 ( Worldometer, 2021 ) . The first case of COVID-19 in Zimbabwe was reported on 21 March 2020 ( Dzobo, M., Chitungo, I., & Dzinamarira, T., 2020 ) ; more than 83, 000 cases and 2,600 deaths have been reported as of 18 July 2021 ( Worldometer, 2021 ) . Zimbabwe has now entered a third wave of the pandemic largely attributed to a more virulent and transmissible delta variant (B.1.617.2) which has caused a surge in infections and deaths in the African region ( Tony Blair Institute of Global Change, 2021 ). The third wave in Zimbabwe began on the 12 th of June as circuit lockdowns were imposed on hotspot districts in Mashonaland West province ( MoHCC, 2021a ). The third wave has seen Zimbabwe experiencing a surge in cases and deaths. For instance, at the time of writing, the number of COVID-19 cases recorded during the third wave (43,769) represents 52% of the total (83, 619 COVID-19) cases recorded in Zimbabwe since the outbreak begun ( MoHCC, 2021a ). COVID-19 prevention in Zimbabwe has been multi-sectoral and the diagnostic laboratory has played a very important role. At present, 128 private laboratories, 26 government laboratories and 3 research laboratories are authorised to conduct SARS-CoV-2 testing and issue results ( MoHCC, 2021 ) . Of all the laboratories performing SARS-CoV-2 diagnostic PCR testing in Zimbabwe, the National Microbiology Reference Laboratory (NMRL) is the only laboratory performing sequencing of the virus for the country's ten provinces. When compared to other countries like Nigeria ( NCDC, 2021 ) and South Africa ( Moorthy, Restrepo, Preziosi & Swaminathan, 2020 ) that have the government and private laboratories working together to conduct sequencing, Zimbabwe's capacity is low. The NMRL is still building capacity for the SAS-CoV-2 virus sequencing. At present, there are two nanopore sequencers (a portable sequencing platform with a throughput of 96 samples per run) received from Africa CDC and the Quadram Institute. NMRL currently relies on the shipment of samples to the Quadram Institute and the Kwazulu-Natal Research Innovation and Sequencing Platform for sequencing to meet the testing needs. There is a need to increase sequencing capacity in Zimbabwe to monitor ongoing SARS-CoV-2 evolution and detection of new SARS-CoV-2 variants to better inform public health responses. This letter highlights the current state of SARS-CoV-2 genomic surveillance and proffers solutions that have the potential to increase genomic surveillance of human pathogens in Zimbabwe. SARS-CoV-2 genome sequencing of samples from patients answer two important questions about the virus: 1) how the virus is mutating into variants and 2) distribution of different clades of SARS-CoV-2 among geographical regions, shedding light on the diversity of strains. Of particular interest are the mutations affecting the spike protein that influences how infectious the virus is, how severe the infection may become, and how well current vaccines protect against the virus. Genomic surveillance can therefore inform and complement strategies to reduce the burden of COVID-19 by providing valuable in- targeted interventions ( WHO, 2021a ). As of June 25, 2021, there have been four SARS-CoV-2 variants of concern (VOCs) that have emerged and undergone transmission around the world. A variant becomes a concern when it exhibits features of increased infectivity and/or transmissibility ( WHO, 2021b ). The emergence of new, more contagious SARS-CoV-2 variants has underscored the need to step up genomic surveillance efforts to better control the pandemic ( Habibzadeh, P., Mofatteh, M., Silawi, M., Ghavami, S., & Faghihi, M. A., 2021 ) . Currently, SARS-CoV-2 sequencing is taking place at the NMRL, the leading government referral laboratory. Funding and training from the African Centre for Disease Control and Prevention (Africa CDC) and Quadram Biosciences Institute (QIB, United Kingdom) has boosted SARS-CoV-2 sequencing in Zimbabwe. A report of the first data on SARS-CoV-2 sequencing in Zimbabwe revealed that the B.1.351 VOC, originally identified in South Africa was present in 74 (69%) of 107 sequenced cases in December 2020, and 99 (95%) of 104 sequenced cases in January 2021 ( Mashe, T., Takawira, F. T., Gumbo, H., Juru, A., Nyagupe, C., Maeka, K. K., et al., 2021 ). As of 18 July 2021, Zimbabwe has submitted a total of 558 SARS-CoV-2 sequences to the GISAID database. The percentage number of cases sequenced and shared to date is 0.667 ( GISAID, 2021 ). However, Zimbabwe has not submitted any sequences in the last 90 days ( GISAID, 2021 ); considering the country is at its peak of COVID-19 infections, more effort needs to be directed towards sequencing to identify variants circulating within the population. Despite the efforts of the Zimbabwean government and its partners, the current state of pathogen genomic surveillance needs improvement to enable surveillance of current and future epidemics. There is limited capacity for SARS-CoV-2 genomic surveillance in Zimbabwe due to limited skillsets and laboratory infrastructural deficiencies. There is an urgent need for funding from the government of Zimbabwe to set up a robust genomic surveillance program to detect SARS-CoV-2 VOCs in Zimbabwe and guide public health responses accordingly. Additionally, partnerships between local public health laboratories, private laboratories, and academia should be strengthened to ensure a coordinated approach to genomic surveillance. COVID-19 genome sequencing laboratory network launches in Africa COVID-19: a perspective for lifting lockdown in Zimbabwe Submission Tracker Global Molecular diagnostic assays for COVID-19: an overview Nanopore sequencing as a rapidly deployable Ebola outbreak tool Surveillance of SARS-CoV-2 in Zimbabwe shows dominance of variants of concern. The Lancet. Microbe Ministry of Health ZW (@MoHCCZim) /Twitter Ministry of health and Child Care Zimbabwe . TESTING UPDATED LIST Data sharing for novel coronavirus (COVID-19) Statement on variants of SARS-COV-2 in Nigeria. Nigeria Centre for Disease Control Variants in Africa: Recommendations for Preventing an Enduring Pandemic A novel coronavirus outbreak of global health concern Genome sequencing central to COVID-19 response | WHO | Regional Office for Africa Tracking SARS-CoV-2 variants COVID Live Update: Cases and Deaths from the Coronavirus -Worldometer None to declare The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors Not applicable